Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Autor:
Gilberto Lopes
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in th
Autor:
Mario Giuliano, Emilia Montagna, Diego D'Agostino, Sabino De Placido, Giuseppe Cancello, Monica Plaitano, Giuseppe Di Lorenzo, Michele De Laurentiis, Antonio Giordano
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines.
Autor:
Yalai Bai, William M. Sikov, David L. Rimm, Maysa M. Abu-Khalaf, Lyndsay Harris, Veerle Bossuyt, Huan Cheng, Natalie Sinclair
Publikováno v:
BMC Cancer
Background Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive (HER2+) breast cancers but traditional methods of measuring HER2 expression
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Autor:
Adrienne Morey, Diana J. Hastrich, David Ingram, Peter C. Willsher, Arlene Chan, Belinda Brown
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 555 (2012)
BMC Cancer
BMC Cancer
Background Overall survival of HER2 positive metastatic breast cancer patients has been significantly improved with inclusion of trastuzumab to chemotherapy. Several studies have demonstrated discordant HER2 status in the primary and metastatic tumou
Autor:
Sarah Kirk, Tania Szado, Lukas C. Amler, Young-Hyuck Im, Jennifer Eng-Wong, Giampaolo Bianchini, Pinuccia Valagussa, Tadeusz Pienkowski, Luca Gianni, Giulia Bianchi, Lila Zabaglo, Mitch Dowsett, Astrid Kiermaier, Mei Ching Liu, Ling Ming Tseng
Publikováno v:
Breast Cancer Research : BCR
Background NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assess
Publikováno v:
BMC Cancer
Background A high neutrophil-to-lymphocyte ratio (NLR) may be related to increased mortality in patients with lung, colorectal, stomach, liver, and pancreatic cancer. To date, the utility of NLR to predict the response to neoadjuvant chemotherapy (NA
Autor:
Shanu Modi, Betsy Althaus, Anthony D. Elias, Ellie Guardino, Alexander Strasak, Dan Lu, Ian E. Krop, Mark D. Pegram, Patricia LoRusso
Publikováno v:
Breast Cancer Research : BCR
Background In pre-clinical studies, the anti-tumor activity of T-DM1 was enhanced when combined with taxanes or pertuzumab. This phase 1b/2a study evaluated the safety/tolerability of T-DM1 + paclitaxel ± pertuzumab in HER2-positive advanced breast
Autor:
A. Rocca, Elisabetta Munzone, Giuseppe Renne, Aron Goldhirsch, Giuseppe Curigliano, Giuseppina Bonizzi, Franco Nolè
Publikováno v:
Breast Cancer Research
Introduction The amounts of estrogen receptor (ER) and progesterone receptor (PgR) in a primary tumor are predictive of the response to endocrine therapies of breast cancer. Several patients with ER-positive primary tumors relapse after adjuvant endo
Autor:
Fountzilas, George, Dafni, U., Bobos, M., Kotoula, V., Batistatou, Anna, Xanthakis, I., Papadimitriou, C., Kostopoulos, I., Koletsa, T., Tsolaki, E., Televantou, D., Timotheadou, E., Koutras, A. K., Klouvas, G. D., Samantas, E., Pisanidis, N., Karanikiotis, C., Sfakianaki, I., Pavlidis, Nicholas, Gogas, H., Linardou, H., Kalogeras, K. T., Pectasides, Dimitrios, Dimopoulos, M. A.
Publikováno v:
BMC Cancer
Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has been associated with respons